Amneal Pharmaceuticals has received U.S. FDA approval for the generic version of mycophenolate mofetil, positioning the company to compete head-to-head in the widely used immunosuppressant market. This approval offers Amneal a significant opportunity to increase market share against major biologics competitors in the transplant and autoimmune therapy sectors.